MTX Enters Earnings Week With Analysts Bullish, Stock Down 6% in a Month

Minerals Technologies Inc. heads into its October 29 earnings release with a wide gap between where analysts think the stock should trade and where the market has taken it.

The stock closed at $62.56 on October 20, down nearly 7% over the past month and off about 2% on the week. The mean analyst price target is $91.25, implying roughly 46% upside from current levels. That gap is unusually wide for a stock with no activist on the register, no short squeeze threat, and no obvious near-term catalyst beyond the earnings print eight days away. The tension is worth paying attention to.

The analyst community is uniformly bullish, though the recent pace of upgrades has slowed. Both active coverage firms, Freedom Capital Markets and Truist Securities, carry Buy ratings with targets in the $90 range. Freedom's David Silver trimmed his target from $92 to $90 in September while maintaining his rating; Truist's Peter Osterland has ratcheted targets steadily higher over the past year, from $80 to $90. No firm has broken ranks with a downgrade. Bulls point to improving order patterns in Household & Personal Care, seasonal strength in Environmental & Infrastructure, and growing project wins for MTX's PFAS remediation product in North America and Europe. Bears focus on a 10% year-over-year sales drop in the Consumer & Specialties segment, destocking from pet care and fabric care customers, and a 6% decline in Engineered Solutions, which together raise questions about how fast the recovery actually arrives. At a trailing P/E of 9.4x and an EV/EBITDA of 6.4x, the valuation is undemanding. The P/E has compressed by more than half a point over the past month, reflecting the stock's slide rather than any earnings revision. The EV/EBIT factor scores in the 74th percentile of the universe, a decent value signal, though EPS momentum ranks in the 28th percentile over the past 30 days, meaning estimate revisions have not been running in the bulls' favour.

Short sellers are not pressing the bear case with much conviction. Short interest is 2.7% of the free float, a low reading that has edged down about 0.7% on the week after a roughly 5% build over the prior month. Borrowing costs have fallen sharply, down 21% on the week and 43% over the past month to just 0.31%, a negligible fee. Availability is extremely loose at over 8,000% of short interest, meaning there is far more stock available to borrow than has been borrowed. The borrow market tells a story of disinterest rather than conviction. Options confirm the same picture: the put/call ratio is 0.44, slightly above its 20-day average of 0.41, but the z-score of 0.91 is well within normal range. None of this looks like a market taking a hard directional view.

One item worth noting in the alt data is a spike in retail attention. Wikipedia page views and ORTEX stock page visits have pushed to a z-score of 4.67 versus the company's own 90-day history, the highest reading in recent months. This is an attention signal, not a revenue or earnings indicator, but the timing is notable with a print due in eight days.

The prior two earnings events offer a reference point. The July 31 and September 22 prints each saw modest positive reactions on the day, with the one-day moves of 3.7% and 0.3% respectively. The five-day outcomes were more mixed: the July release held its gains, while the September event faded slightly. With the stock already 7% lower than where it traded around those events, the setup going into October 29 is one where the discount is visible but the near-term direction depends entirely on what management says about the order book and margin trajectory across its two main segments.

The earnings release in eight days is the clearest near-term focal point: specifically whether Consumer & Specialties segment revenues show any stabilisation, and whether PFAS project momentum has translated into revenue rather than just pipeline.